Beta
Bifidobacterium infantis 35624
supplementClinically proven for IBS relief.
Reported Benefits
Immunomodulatory effects in healthy subjects following consumption of Bifidobacterium infantis 35624
Konieczna P, Groeger D, et al.
B. infantis 35624 promoted immuno-regulatory responses in healthy subjects, enhancing tolerance in the gastrointestinal mucosa and suggesting potential for reducing inflammation systemically.
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.
Groeger D, O'Mahony L, Murphy EF, et al.
Oral administration of B. infantis 35624 for 6-8 weeks reduced plasma CRP, TNF-ฮฑ, and IL-6 levels in patients with ulcerative colitis, chronic fatigue syndrome, and psoriasis, normalizing cytokine profiles to levels seen in healthy volunteers. The strain demonstrated systemic anti-inflammatory effects.
An open-label study to assess the effect of Bifidobacterium longum 35624 on symptoms of irritable bowel syndrome in children and adolescents with vitamin D deficiency
Cruchet Munoz S, et al.
In 58 children and adolescents with IBS, 12 weeks of 1x10^9 CFU daily significantly decreased abdominal pain frequency and severity, distension, and life impact, while improving bowel habit satisfaction, independent of vitamin D status. The probiotic was well-tolerated with no adverse effects noted.
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Whorwell PJ, Altringer L, Morel J, et al.
In women with IBS, 1x10^8 CFU of B. infantis 35624 significantly reduced abdominal pain, bloating, bowel dysfunction, and gas compared to placebo after 4 weeks, with global symptom improvement exceeding placebo by over 20%. No significant adverse events were reported.
Immunomodulatory effects in healthy subjects following consumption of Bifidobacterium infantis 35624
Konieczna P, Groeger D, et al.
B. infantis 35624 promoted immuno-regulatory responses in healthy subjects, enhancing tolerance in the gastrointestinal mucosa and suggesting potential for reducing inflammation systemically.
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.
Groeger D, O'Mahony L, Murphy EF, et al.
Oral administration of B. infantis 35624 for 6-8 weeks reduced plasma CRP, TNF-ฮฑ, and IL-6 levels in patients with ulcerative colitis, chronic fatigue syndrome, and psoriasis, normalizing cytokine profiles to levels seen in healthy volunteers. The strain demonstrated systemic anti-inflammatory effects.
An open-label study to assess the effect of Bifidobacterium longum 35624 on symptoms of irritable bowel syndrome in children and adolescents with vitamin D deficiency
Cruchet Munoz S, et al.
In 58 children and adolescents with IBS, 12 weeks of 1x10^9 CFU daily significantly decreased abdominal pain frequency and severity, distension, and life impact, while improving bowel habit satisfaction, independent of vitamin D status. The probiotic was well-tolerated with no adverse effects noted.
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Whorwell PJ, Altringer L, Morel J, et al.
In women with IBS, 1x10^8 CFU of B. infantis 35624 significantly reduced abdominal pain, bloating, bowel dysfunction, and gas compared to placebo after 4 weeks, with global symptom improvement exceeding placebo by over 20%. No significant adverse events were reported.
An open-label study to assess the effect of Bifidobacterium longum 35624 on symptoms of irritable bowel syndrome in children and adolescents with vitamin D deficiency
Cruchet Munoz S, et al.
In 58 children and adolescents with IBS, 12 weeks of 1x10^9 CFU daily significantly decreased abdominal pain frequency and severity, distension, and life impact, while improving bowel habit satisfaction, independent of vitamin D status. The probiotic was well-tolerated with no adverse effects noted.
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Whorwell PJ, Altringer L, Morel J, et al.
In women with IBS, 1x10^8 CFU of B. infantis 35624 significantly reduced abdominal pain, bloating, bowel dysfunction, and gas compared to placebo after 4 weeks, with global symptom improvement exceeding placebo by over 20%. No significant adverse events were reported.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Irritable Bowel Syndrome
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Whorwell PJ, Altringer L, Morel J, et al.
In women with IBS, 1x10^8 CFU of B. infantis 35624 significantly reduced abdominal pain, bloating, bowel dysfunction, and gas compared to placebo after 4 weeks, with global symptom improvement exceeding placebo by over 20%. No significant adverse events were reported.
An open-label study to assess the effect of Bifidobacterium longum 35624 on symptoms of irritable bowel syndrome in children and adolescents with vitamin D deficiency
Cruchet Munoz S, et al.
In 58 children and adolescents with IBS, 12 weeks of 1x10^9 CFU daily significantly decreased abdominal pain frequency and severity, distension, and life impact, while improving bowel habit satisfaction, independent of vitamin D status. The probiotic was well-tolerated with no adverse effects noted.
Research (4 studies)
Community updates
No updates yet for this supplement.
Be the first to share your experience!